Translational Breast Radiobiology Group
Dr Navita Somaiah's group are investigating the optimisation of radiotherapy by improving tumour response to improve personalised treatments.
We are investigating cell and molecular determinants of sensitivity to radiotherapy fraction size to enable personalised fractionation approaches.
Radiotherapy is widely used in the treatment of cancer and typically delivered in small daily doses (fractions) with the aim of sparing normal tissues relative to cancers. However, recent clinical trials led by ICR/RM in breast and prostate cancer, have led to increasing interest in hypofractionation (use of fractions >2Gy).
We are investigating cell and molecular determinants of sensitivity to radiotherapy fraction size to enable personalised fractionation approaches.
Finally, to exploit a therapeutic gain between normal tissue toxicity and tumour control, the group are using novel approaches such as big data analytics to identify predictors of normal tissue toxicity following radiotherapy.
Dr Navita Somaiah
Group Leader:
Translational Breast Radiobiology
Dr Navita Somaiah is a clinician scientist at The Institute of Cancer Research, London, and a clinical oncologist at The Royal Marsden. She is the first recipient of a prestigious Clinician Scientist Fellowship at the ICR.
Researchers in this group
.
OrcID: 0000-0002-0386-992X
Phone: +44 20 3437 6232
Email: [email protected]
Also on: @megan_celyn
Location: Sutton
Dr Navita Somaiah's group have written 54 publications
Most recent new publication 12/2024
See all their publications
